Cinclus Pharma Holding AB Company Description

Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China.

The company’s lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease.

It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H.

pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden.

Cinclus Pharma Holding AB (publ)

Country	Sweden
Founded	2014
Industry	Drug Manufacturers - Specialty & Generic
Sector	Healthcare
Employees	18
CEO	Christer Ahlberg

Contact Details

Address: Kungsbron 1 Stockholm, 11122 Sweden
Phone	46 8 13 33 10
Website	cincluspharma.com

Stock Details

Ticker Symbol	CINPHA
Exchange	Nasdaq Stockholm
Fiscal Year	January - December
Reporting Currency	SEK
ISIN Number	SE0020388577
SIC Code	2834

Key Executives

Name	Position
Christer Ahlberg	Chief Executive Officer and President
Dr. Lennart Hansson Ph.D.	Co-founder and Chairman of the Board
Peter Unge	Co-founder and Director
Maria Engstrom	Chief Financial Officer
Jesper Wiklund	Director of Corporate and Business Development
Kajsa Larsson	Chief Medical Officer